Patents by Inventor Robert J. Altenbach

Robert J. Altenbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potassium channel openers
    Publication number: 20020028836
    Abstract: Compounds of formula I: 1
    Type: Application
    Filed: February 5, 2001
    Publication date: March 7, 2002
    Inventors: Robert J. Altenbach, Hao Bai, Jorge D. Brioni, William A. Carroll, Murali Gopalakrishnan, Robert J. Gregg, Mark W. Holladay, Peggy P. Huang, John F. Kincaid, Michael E. Kort, Philip R. Kym, John K. Lynch, Arturo Perez-Medrano, Henry Q. Zhang
  • Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
    Publication number: 20020007059
    Abstract: Compounds of formula I 1
    Type: Application
    Filed: February 7, 2001
    Publication date: January 17, 2002
    Inventors: Irene Drizin, Robert J. Altenbach, William A. Carroll
  • Pyrano, piperidino, and thiopyrano compounds and methods of use
    Patent number: 6191140
    Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: February 20, 2001
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
  • Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic compounds
    Patent number: 6046207
    Abstract: The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: April 4, 2000
    Inventors: Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, James F. Kerwin, Jr., Michael D. Wendt, Anthony R. Haight, Weijiang Zhang
  • Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adenergic compounds
    Patent number: 5891882
    Abstract: The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: April 6, 1999
    Assignee: Abbott Laboratories
    Inventors: Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, James F. Kerwin, Jr., Michael D. Wendt
  • Bicyclic substituted hexahydrobenz ?e! isoindole alpha-1 adrenergic antagonists
    Patent number: 5792767
    Abstract: The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 11, 1998
    Assignee: Abbott Laboratories
    Inventors: Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, James F. Kerwin, Jr., Suzanne A. Lebold, Edmund L. Lee, John K. Pratt, Kevin B. Sippy, Karin R. Tietje, Diane M. Yamamoto
  • Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
    Patent number: 5597823
    Abstract: The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an .alpha.-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 28, 1997
    Assignee: Abbott Laboratories
    Inventors: Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, Steven W. Elmore, James F. Kerwin, Jr., Suzanne A. Lebold, Edmund L. Lee, Kevin B. Sippy, Karin R. Tietje, Michael D. Wendt
  • Bicyclic substituted hexahydrobenz[e]isoindole .alpha.-1 adrenergic antagonists
    Patent number: 5521181
    Abstract: The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: May 28, 1996
    Assignee: Abbott Laboratories
    Inventors: Michael D. Meyer, Robert J. Altenbach, William A. Carroll, Irene Drizin, Suzanne A. Lebold, Edmund L. Lee, Kevin B. Sippy, Karin R. Tietje, Diane M. Yamamoto, James F. Kerwin, Jr.
  • Biogentic amine uptake inhibitors
    Patent number: 5248677
    Abstract: Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein m is 0, 1 or 2 and n is 0 or 1;R.sup.1 is hydrogen or lower alkyl;R.sup.2 is C.sub.1 -C.sub.6 -alkyl substituted with a heterocyclic group or C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino;R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen, and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; andR.sup.7 is hydrogen or C.sub.1 -C.sub.6 -alkyl.
    Type: Grant
    Filed: September 18, 1992
    Date of Patent: September 28, 1993
    Assignee: Abbott Laboratories
    Inventors: Fatima Z. Basha, John F. DeBernardis, Robert J. Altenbach
  • Biogenic amine uptake inhibitors
    Patent number: 5180733
    Abstract: Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein M is 0, 1 or 2 and n is 0 or 1;R.sup.1 is hydrogen or lower alkyl;R.sup.2 is C.sub.1 -C.sub.6 -alkyl substituted with a heterocyclic group or C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino;R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen, and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; andR.sup.7 is hydrogen or C.sub.1 -C.sub.6 -alkyl.
    Type: Grant
    Filed: March 22, 1991
    Date of Patent: January 19, 1993
    Assignee: Abbott Laboratories
    Inventors: Fatima Z. Basha, John F. DeBernardis, Robert J. Altenbach